High-sensitivity C-reactive protein (hsCRP) is more sensitive to inflammatory reactions than CRP and initially was found to be useful for predicting cardiovascular risk.
1
In addition, HsCRP is reported to be associated with cancer prognosis, and a recent study validated the ability of preoperative hsCRP to predict postoperative prognosis among cancer patients. 2, 3 However, data are inadequate regarding whether pre-or postoperative hsCRP levels have better predictive value after oncologic surgery.
PRESENT
In our study, 4 both elevated pre-and postoperative hsCRP levels were associated with increased risks of 90-day mortality after surgery for thoracic and abdominal cancers. However, preoperative hsCRP had better prognostic value than postoperative hsCRP. Additionally, preoperative hsCRP had the best predictive value for lung and esophageal cancers, whereas postoperative hsCRP had the best predictive value for urologic cancer.
FUTURE
Although this study demonstrated the abilities of preand postoperative high-sensitivity C-reactive protein levels to predict 90-day mortality after surgery for abdominal and thoracic cancers, it had some limitations due to the nature of its retrospective design. Therefore, prospective study should be performed to confirm the abilities of pre-and postoperative hsCRP levels to predict long-term mortality after surgery for cancers.
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